Advertisement
Research ArticleArticle

The Pore Loop Domain of TRPV1 Is Required for Its Activation by the Volatile Anesthetics Chloroform and Isoflurane

Corinna Kimball, Jialie Luo, Shijin Yin, Hongzhen Hu and Ajay Dhaka
Molecular Pharmacology July 2015, 88 (1) 131-138; DOI: https://doi.org/10.1124/mol.115.098277

Abstract

The environmental irritant chloroform, a naturally occurring small volatile organohalogen, briefly became the world’s most popular volatile general anesthetic (VGA) before being abandoned because of its low therapeutic index. When chloroform comes in contact with skin or is ingested, it causes a painful burning sensation. The molecular basis for the pain associated with chloroform remains unknown. In this study, we assessed the role of transient receptor potential (TRP) channel family members in mediating chloroform activation and the molecular determinants of VGA activation of TRPV1. We identified the subpopulation of dorsal root ganglion (DRG) neurons that are activated by chloroform. Additionally, we transiently expressed wild-type or specifically mutated TRP channels in human embryonic kidney cells and used calcium imaging or whole-cell patch-clamp electrophysiology to assess the effects of chloroform or the VGA isoflurane on TRP channel activation. The results revealed that chloroform activates DRG neurons via TRPV1 activation. Furthermore, chloroform activates TRPV1, and it also activates TRPM8 and functions as a potent inhibitor of the noxious chemical receptor TRPA1. The results also indicate that residues in the outer pore region of TRPV1 previously thought to be required for either proton or heat activation of the channel are also required for activation by chloroform and isoflurane. In addition to identifying the molecular basis of DRG neuron activation by chloroform and the opposing effects chloroform has on different TRP channel family members, the findings of this study provide novel insights into the structural basis for the activation of TRPV1 by VGAs.

Introduction

The transient receptor potential vanilloid type 1 (TRPV1) cation channel is promiscuously activated or potentiated by a wide range of noxious and inflammatory stimuli, including temperatures above ∼42°C, acids, bases, capsaicin, and inflammatory molecules like bradykinin (Julius, 2013). Similarly, TRPA1 is a sensor of noxious chemical stimuli such as isothiocyanates, the pungent agents in mustard oil, volatile air pollutants such as acrolein and formalin, endogenous products of oxidative and nitrative stress and inflammatory factors such as bradykinin and ATP (Julius, 2013). Both receptors are expressed in a population of small diameter nociceptive somatosensory neurons (C fibers), with TRPA1 being expressed in a subset of TRPV1+ neurons (Dhaka et al., 2006). Null mutation studies have confirmed essential roles for TRPV1 and TRPA1 in acute and inflammatory nociception (Caterina et al., 2000; Bautista et al., 2006).

Volatile general anesthetics (VGAs) comprise a diverse group of chemicals that are able to reversibly inhibit central nervous system activity, rendering patients unresponsive to stimuli, although the molecular mechanisms by which they act are still somewhat open to debate. Most reports indicate that VGAs bind directly to ligand-gated ion channels/receptors, whereas others suggest that VGAs may act directly on the lipid bilayer to influence neuronal activity (Franks, 2008; Lynch, 2008). VGAs have enabled hundreds of million surgeries annually worldwide, saving countless lives. Perhaps paradoxically, VGAs have been reported to activate nociceptive A-δ and C-fiber neurons in several animal models (Campbell et al., 1984; MacIver and Tanelian, 1990; Mutoh et al., 1998). Moreover, VGAs appear to activate exclusively capsaicin-sensitive or TRPV1+ sensory neurons (Mutoh et al., 1998). Indeed, volatile anesthetics such as isoflurane and desflurane are perceived as pungent and cause airway irritation when inhaled, which has limited their use as induction agents (Eger, 1995; TerRiet et al., 2000). Following up on these findings showed that these VGAs directly activate TRPA1 and sensitize TRPV1 (Cornett et al., 2008; Matta et al., 2008; Eilers et al., 2010). It has therefore been hypothesized that VGAs can elevate postsurgical pain through direct action on these TRP channels.

Chloroform, a small volatile organohalogen, is a naturally occurring environmental irritant that is produced by many seaweeds and algae. It is produced synthetically at an industrial scale (93–350 million pounds/year) and is a commonly used solvent, bonding agent, a precursor to Teflon and refrigerants, and was once found in many consumer products (Winslow and Gerstner, 1978; Li et al., 1993). It is best known as one of the earliest used VGAs. Discovered in the latter 19th century, it quickly became the most popular general anesthetic. It was abandoned in the early 20th century because of its low therapeutic index, as the effective anesthetic dose did not differ markedly from doses that would induce cardiac arrest. Prolonged exposure to chloroform has also been shown to be toxic to organs, tissues, and cells (Winslow and Gerstner, 1978).

Here, we report that chloroform directly activates TRPV1 while also being a reversible inhibitor of TRPA1 and that TRPV1 mediates most responses of dorsal root ganglion (DRG) neurons to chloroform. Chloroform acts synergistically with heat and protons to potentiate TRPV1 activity. Furthermore, we found that residues in the outer pore domain of TRPV1 required for heat- or proton-induced channel activation are also required for activation of the channel by chloroform and isoflurane.

Materials and Methods

Ratiometric Calcium Imaging.

We isolated DRGs from 6- to 12-week-old C57Bl/6J mice. All experiments were performed in compliance with institutional animal care and use committee standards. Dissociation and culturing of mouse DRG neurons were performed as described with the following modifications (Story et al., 2003). Dissected DRGs were dissociated by incubation for 1 hour at 37°C in a solution of culture medium [Ham’s F12/Dulbecco’s modified Eagle’s medium (DMEM) with 10% horse serum, 1% penicillin-streptomycin (Life Technologies, Carlsbad, CA)] containing 0.125% collagenase (Worthington Biochemicals, Lakewood, NJ), followed by a 30-minute incubation in 10 ml of culture media plus 1.25 units of papain. Ca2+ imaging was performed essentially as described previously (Story et al., 2003). Growth media were supplemented with 100 ng/ml nerve growth factor. For experiments involving heterologous expression, human embryonic kidney (HEK) 293T cells were transiently transfected, cotransfected with piresegfp and one of the following: rTrpv1, rTrpv1 H378Q, rTrp1 N628K, N652T, Y653T, rTrpv1 N628K, rTrpv1 N652T, rTrpv1 Y653T, rTrpv1 E600V, mTrpv1 E649Q, or hTrpa1. The threshold for activation was defined as 20% above baseline for chloroform and 30% above baseline for capsaicin/allyl isothiocyanate (AITC) for DRG experiments and heterologous expression experiments. Student’s t test was used for all statistical calculations. All averaged traces represent mean ± S.E.M. The buffer solution for all experiments was 1× Hanks’ balanced salt solution (HBSS) (Invitrogen, Carlsbad, CA), 10 mM HEPES (Invitrogen), except for studies involving acidic or basic solutions, where 1× Hanks’ balanced salt solution was buffered with 10 mM citric acid or 10 mM TRIS (Sigma-Aldrich, St. Louis, MO), respectively. To determine the chloroform responses of TRPV1-transfected HEK cells, background chloroform responses from untransfected HEK cells were subtracted. All dose-response curves and mutant channel experiments were normalized except when noted to peak capsaicin (1 μM) for TRPV1, AITC (100 μM) for TRPA1, or menthol (250 μM) for TRPM8-based experiments to account for experiment/transfection variability. Although channel desensitization could potentially skewer results, causing an overestimation of chloroform activity, we did not observe changes in peak channel responses that corresponded with increases in chloroform concentration and the variability of peak responses across all experiments was minor (data not shown).

Electrophysiology.

Whole-cell patch-clamp recordings in HEK293 cells expressed TRPA1 or TRPV1. HEK293T cells were grown as a monolayer using passage numbers less than 30 and maintained in DMEM (Life Technologies), supplemented with 10% fetal bovine serum (Life Technologies), 100 U/ml penicillin (Life Technologies), and 100 μg/ml streptomycin (Life Technologies) in a humidified incubator at 37°C with 5% CO2. The cells were transiently transfected with 100 ng cDNA of mouse Trpv1 (mTrpv1) or 100 ng of cDNA of mouse Trpa1 (mTrpa1) and 100 ng cDNA of C1-GFP, using Lipofectamine 2000 (Invitrogen). After transfection, the cells were maintained in DMEM at 37°C for 24 hours before use.

Whole-cell patch-clamp recordings were performed using an EPC10 amplifier (HEKA Elektronik Dr. Schulze GmbH, Lambrecht, Germany) at room temperature (22–24°C) on a stage of an inverted phase-contrast microscope equipped with a filter set for green fluorescence protein visualization. Pipettes pulled from borosilicate glass (Sutter Instruments, Novato, CA) with a Sutter P-97 pipette puller had resistances of 2–4MΩ for whole-cell recordings when filled with pipette solution containing 140 mM CsCl, 2 mM EGTA, and 10 mM HEPES with pH 7.3 and 315 mOsm/l osmolarity. A Ca2+-free extracellular solution was used for whole-cell recording to avoid Ca2+-dependent desensitization of TRP channels, containing (in millimolar): 140 NaCl, 5 KCl, 0.5 EGTA, 1 MgCl2, 10 glucose, and 10 HEPES (pH was adjusted to 7.4 with NaOH, and the osmolarity was adjusted to ≈340 mOsm/l with sucrose). The whole-cell currents were recorded using voltage ramps from −100 to +100 mV for 500 milliseconds at holding potential of 0 mV. Data were acquired using Patchmaster software (HEKA Elektronik Dr. Schulze GmbH). Currents were filtered at 2 kHz and digitized at 10 kHz. Data were analyzed and plotted using Clampfit 10 (Molecular Devices, Sunnyvale, CA).

Reagents.

Chloroform, isoflurane, AITC, capsaicin, menthol, AMG9810 [(2E)-N-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[4-(1,1-dimethylethyl)phenyl]-2-propenamide], 2-aminoethoxy diphenyl borate, GSK1016790A [N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide; GSK101], and all other reagents were obtained from Sigma-Aldrich unless otherwise noted.

Statistics.

All statistics reported used the student’s t test except when noted. Statistical effects of chloroform on temperature, pH, or capsaicin on TRPV1 activity were measured by analysis of variance. All error reported as S.E.M.

Results

Chloroform Activates Capsaicin-Sensitive DRG Neurons.

Nociceptive DRG neurons are specialized to sense noxious chemical and physical stimuli in tissues such as the skin, muscles, and internal organs (Dhaka et al., 2006). Using Ca2+ imaging, we observed that 40% of DRG neurons responded to chloroform (0.1% or 12.5 mM), and the vast majority of these neurons (78%) also responded to the TRPV1 agonist capsaicin (Fig. 1, A and B). It is therefore possible that the pain and irritation associated with chloroform ingestion, as well as eye and skin contact, could be caused by the direct activation of nociceptive sensory neurons. Since the vast majority of chloroform-responsive neurons were also activated by capsaicin, we investigated whether TRPV1 was required for the neuronal responses elicited by chloroform. Pharmacologic blockade of TRPV1 with the specific TRPV1 antagonist AMG9810 inhibited responses to chloroform within the capsaicin-sensitive population, as well as neurons that did not respond to capsaicin, suggesting that many non–capsaicin-responding DRG neurons that responded to chloroform were TRPV1 expressing neurons (360:380 fluorescence ratio to chloroform (9.4 mM); capsaicin(+), 0.58 ± 0.06 versus capsaicin(+) + AMG9810 (1 μM), 0.09 ± 0.009, P < 0.001; capsaicin(−), 0.21 ± 0.02 versus capsaicin(−) + AMG9810 (1 μM), 0.091 ± 0.01, P < 0.001) (Fig. 1, C and D) (Gavva et al., 2005).

Fig. 1.
Fig. 1.

DRG neuron response to chloroform (Chlor.) is mediated primarily by TRPV1. Responses of dissociated DRG neurons were assessed using ratiometric calcium imaging. (A) Chloroform-sensitive neurons are localized primarily within the capsaicin (Caps.)-sensitive population. DRG neurons from C57Bl/6J were challenged with a pulse of chloroform (12.5 mM), followed by a pulse of capsaicin (1 μM). (B) Average peak response over baseline to chloroform of capsaicin-sensitive and capsaicin-insensitive DRG neurons (n = 4 trials, 30–100 neurons/trial with each trial weighted to account for number of neurons). (C) The TRPV1 antagonist AMG9810 (1 μM) blocks chloroform (9.4 mM) responses in capsaicin-sensitive and capsaicin-insensitive neurons. (D) Average peak response over baseline to chloroform (9.4 mM) of DRG neurons preincubated with AMG9810 (1μM) or vehicle only of capsaicin-sensitive and capsaicin-insensitive neurons (n = 4 trials, 30–100 neurons/trial with each trial weighted to account for number of neurons). **P < 0.01; ***P < 0.001.

Previous studies have suggested that VGAs do not directly activate TRPV1 but rather sensitize the channel to activation by capsaicin, protons, and heat (Cornett et al., 2008). We found that application of chloroform elicited a strong influx of calcium in TRPV1-expressing HEK cells that can be blocked by TRPV1 antagonist AMG9810 (Fig. 2, A and B). Furthermore, application of chloroform produced inward currents in voltage-clamped TRPV1-expressing cells that were also blocked by AMG9810 (TRPV1 basal: 86 ± 31 pA/pF, TRPV1 + chloroform (9.4 mM): 215 ± 42 pA/pF, TRPV1 + chloroform (9.4 mM) + AMG9810 (1 μM): 85 ± 19 pA/pF; measured at +100 mV, n = 7 cells/condition) (Fig. 2C). Using Ca2+-imaging, we found that chloroform activated TRPV1-expressing cells in a dose-dependent manner with an EC50 of 9.18 mM (Fig. 2D). These data argue that TRPV1 is directly activated by chloroform.

Fig. 2.
Fig. 2.

TRPV1 is activated by chloroform (Chlor.). (A) Using ratiometric calcium imaging, TRPV1-expressing HEK cells (red) respond to chloroform (9.4 mM) and capsaicin (Caps., 1 μM). Untransfected HEK cells (black). (B) Preincubation with AMG9810 blocks the responses of TRPV1-expressing HEK cells (red) to chloroform. Untransfected HEK cells (black). (C) Chloroform (9.4 mM, red) increases TRPV1 channel activity recorded using whole-cell configuration with TRPV1-expressing HEK cells in an AMG9810 (1 μM, blue) dependent manner. Whole-cell patches were challenged with a voltage-ramp protocol. (D) Dose-response curve of TRPV1-expressing HEK cells to chloroform normalized to peak capsaicin response (1 μM) using ratiometric calcium imaging (n ≥ 3 trials/concentration, about 100 cells/trial with each trial weighted to account for number of cells).

Since other VGAs have been shown to activate the noxious chemosensor TRPA1, we investigated whether chloroform also activated this pain-initiating channel (Matta et al., 2008). Interestingly, isoflurane, which activated TRPA1 with an EC50 ∼ 0.18 mM, was shown to have pore-blocking effects at concentrations above 2.7 mM (Matta et al., 2008). We found that chloroform at concentrations above 0.075% (9.4 mM) did not activate TRPA1 as observed via Ca2+ imaging and whole-cell patch-clamp experiments (Fig. 3, A and B) (Matta et al., 2008). Chloroform did seem to reduce intracellular calcium levels in TRPA1-expressing HEK cells, suggesting that it might be inhibiting baseline TRPA1 activity (Fig. 3, A and B). Indeed, using Ca2+ imaging, we found that preincubation with chloroform blocked AITC-mediated activation of TRPA1 in a dose-dependent manner (IC50 = 0.046 mM) with inhibition seen at concentrations as low as 50 μM; like the TRPA1 antagonist HC-030031 [2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl)acetamide], chloroform potently and reversibly inhibited TRPA1 activity (Fig. 3, C and D) (McNamara et al., 2007). Unlike isoflurane, chloroform at concentrations as low as 10 μM did not appear to activate TRPA1, implying that these VGAs interact with the channel differentially.

Fig. 3.
Fig. 3.

TRPA1 is inhibited by chloroform (Chlor.). (A) Chloroform (9.4 mM) appears to suppress baseline activity in TRPA1-expressing HEK cells (red), which are potently activated by the TRPA1 agonist AITC (100 μM), whereas no change is seen in baseline activity of untransfected HEK cells (black). (B) Whole-cell recording using a voltage-ramp protocol of TRPA1 expressing HEK cell shows no increase in current to chloroform (9.4 mM, red) while showing potent increases in current to AITC (100 μM). At +100mV; TRPA1 basal: 89 ± 27 pA/pF; TRPA1 + chloroform (9.4 mM): 35 ± 6 pA/pF; TRPA1 + AITC (100 μM): 442 ± 77 pA/pF; n = 5 cells/condition. (C) Preincubation with chloroform inhibits activation of TRPA1-expressing HEK cells by AITC (5 μM) in a dose-dependent manner as measured by ratiometric calcium imaging (n ≥ 3 trials/concentration, about 100 cells/trial, with each trial weighted to account for the number of cells). (D) Chloroform is a reversible antagonist of TRPA1. Chloroform (9.4 mM) reversibly suppresses AITC (5 μM) mediated activation of TRPA1-expressing HEK cells (black).

We next investigated the effects of chloroform on other thermoTRPs (Dhaka et al., 2006). None of the heat-activated channels TRPV2, TRPV3, or TRPV4 was activated by chloroform at a concentration that elicited a robust activation of TRPV1; however, they did respond robustly to their known agonists, indicating that the channels were functional in our experiments (Fig. 4, A–C). However, the cold-activated channel TRPM8 was activated by chloroform (9.4 mM), in line with previous reports that TRPM8 activity is modulated by VGAs (Fig. 4D) (McKemy et al., 2002; Peier et al., 2002; Vanden Abeele et al., 2013). Furthermore, TRPM8 was activated in a dose-dependent manner by chloroform with an EC50 of 7.95 mM (Supplemental Fig. 1A; data not shown). To determine whether TRPM8 could be contributing to chloroform-evoked DRG responses, we used Ca2+ imaging to measure the response of isolated enhanced green fluorescent protein farnesylated (EGFPf)–positive DRG neurons from a previously characterized TRPM8-EGFPf knock-in mouse line where EGFPf-expressing neurons from heterozygous animals were shown to express TRPM8 (Dhaka et al., 2008). EGFPf-expressing DRG neurons from heterozygous TRPM8Egfpf/+ mice were found to be responsive to chloroform. Furthermore, capsaicin-insensitive, menthol-sensitive EGFPf-expressing neurons were found to be significantly more responsive to chloroform (9.4 mM) versus EGFPf-negative/capsaicin-insensitive neurons, indicating that TRPV1 was not contributing to chloroform responsiveness of these neurons (360/380 fluorescence ratio to chloroform (9.4 mM): EGFPf(+)/capsaicin(+), 1.4 ± 0.29 (n = 16 neurons), EGFPf(+)/capsaicin(−), 0.90 ± 0.28 (n = 9 neurons) or EGFPf(−)/capsaicin(+), 0.89 ± 0.11 (n = 152 neurons) versus EGFPf(−)/capsaicin(−), 0.22 ± 0.02 (n = 215); P < 0.001, P < 0.05, P < 0.001, respectively) (Supplemental Fig. 1B). These data suggest that, in addition to TRPV1, TRPM8 could contribute to DRG neuronal responses to chloroform.

Fig. 4.
Fig. 4.

Chloroform (Chlor.) does not activate TRPV2, TRPV3, or TRPV4, but it does activate TRPM8. Responses of TRP channel–expressing HEK cells were assessed with ratiometric calcium imaging. (A) Chloroform (9.4 mM) does not activate TRPV2, which is activated by known agonist 2-aminoethoxy diphenyl borate (2-APB; 100 μM) (Hu et al., 2004). (B) TRPV3 does not respond to chloroform (9.4 mM) but is activated by known agonist 2-APB (100 μM) (Hu et al., 2004). (C) TRPV4, which is activated by known agonist GSK101 (10 nM), is not activated by chloroform (9.4 mM) but is activated by a known agonist (Thorneloe et al., 2008). (D) TRPM8 is activated by chloroform (9.4 mM) and its known agonist, menthol (Peier et al., 2002).

Chloroform Potentiates Heat- and pH-Induced Activation of TRPV1 but Not Activation by Capsaicin.

Many TRPV1 agonists act cooperatively to potentiate the activity of the channel. Protons, for example, potentiate the responses of the channel to heat or capsaicin. Isoflurane has also been shown to potentiate activation of TRPV1 by both heat and capsaicin (Cornett et al., 2008). Using Ca2+ imaging, we investigated the ability of chloroform to act cooperatively with other TRPV1 agonists. We found that 6.3 mM chloroform, a concentration that shows minimal or no activation of TRPV1, potently shifted thermal activation of TRPV1 toward cooler temperatures (Fig. 5A) (i.e., TRPV1 has a thermal threshold near 42°C, but in the presence of 6.3 mM, chloroform activation of the channel was seen at temperatures ≥29°C). This activation was greater than the additive activation of the channel by 6.3 mM chloroform at baseline temperature (24.5°C) or temperature alone, suggesting a synergistic interaction between temperature and chloroform [the effect of chloroform (6.3 mM) on heat activation of TRPV1, P < 0.001; 24.5°C, 1.1 ± 0.49 absorbance unit (a.u.) (n = 221 cells) versus 24.5°C + chloroform, 10.0 ± 1.36 a.u. (n = 667 cells); 29°C, 1.7 ± 0.1 a.u. (n = 128 cells) versus 29°C + chloroform, 33.0 ± 3.15 a.u. (n = 175 cells); 34°C, 4.9 ± 0.83 a.u. (n = 242 cells) versus 34°C + chloroform, 24.9 ± 6.82 a.u. (n = 79 cells); 38°C, 6.3 ± 2.00 a.u. (n = 127 cells) versus 38°C + chloroform, 44.4 ± 7.92 a.u. (n = 129 cells); 39°C 16.7 ± 4.35 a.u. (n = 234 cells) versus 38°C + chloroform, 42.3 ± 4.98 a.u. (n = 403 cells); 44°C 36.8 ± 7.89 a.u. (n = 153 cells) versus 44°C + chloroform, 53.1 ± 7.72 a.u. (n = 211 cells)]. Chloroform (6.3 mM) also potentiated TRPV1 responses to protons with activation of the channel at pH 5.5 greater than additive of each stimulus alone, and there was a significant effect of chloroform on acidic pH activation of TRPV1 (P < 0.001; pH5, 81.9 ± 7.89 (n = 145 cells) versus pH 5 + chloroform, 94.6 ± 10.19 (n = 125 cells); pH 5.5, 45.9 ± 4.36 (n = 130 cells) versus pH 5.5 + chloroform, 63.0 ± 0.78 (n = 150 cells); pH 6, 4.3 ± 1.21 (n = 223 cells) versus pH 6 + chloroform, 9.4 ± 0.94 (n = 273 cells); pH 6.2, 2.8 ± 0.84 (n = 60 cells) versus pH 6.2 + chloroform, 5.7 ± 2.46 (n = 97 cells; pH 6.5, 1.8 ± 0.71 (n = 222 cells) versus pH 5 + chloroform, 6.4 ± 0.90 (n = 247 cells)) (Fig. 5B). Surprisingly, capsaicin-mediated activation of TRPV1 was not synergistically potentiated by 6.3 mM chloroform. Instead, we observed that 6.3 mM chloroform had a merely additive effect on channel activation by this agent at concentrations less than or equal to 5 nM capsaicin. Concentrations greater than 10 nM capsaicin yielded indistinguishable activations in the presence or absence of chloroform (effect of chloroform (6.3 mM) on capsaicin-mediated activation of TRPV1, P > 0.05; capsaicin (1 nM), 0.23 ± 0.11 (n = 260 cells) versus capsaicin (1 nM) + chloroform, 0.51 ± 0.06 (n = 108 cells); capsaicin (5 nM), 0.20 ± 0.11 (n = 115 cells) versus capsaicin (5 nM) + chloroform, 0.75 ± 0.15 (n = 79 cells); capsaicin (10 nM), 2.39 ± 0.62 (n = 304 cells) versus capsaicin (10 nM) + chloroform, 2.32 ± 0.96 (n = 95 cells); capsaicin (20nM), 3.74 ± 0.38 (n = 167 cells) versus capsaicin (20 nM) + chloroform, 4.24 ± 0.17 (n = 221 cells); capsaicin (50 nM), 4.81 ± 0.33 (n = 260 cells) versus capsaicin (1 nM) + chloroform, 5.64 ± 1.01 (n = 108 cells); all units: peak Δ of 360/380 ratio to stimulus) (Fig. 5C).

Fig. 5.
Fig. 5.

Chloroform (Chlor.) potentiates TRPV1 activation by heat and protons, but capsaicin does not. Responses of TRPV1-expressing HEK cells were assessed using ratiometric calcium imaging. (A) Temperature response curve in the presence or absence of chloroform (6.3 mM). (B) Proton response curve in the presence or absence of chloroform (6.3 mM). (C) Capsaicin response curve in the presence or absence of chloroform (6.3 mM). All data points for (A) and (B) correspond to peak activation to stimulus normalized to peak response to a subsequent pulse of capsaicin (1 μM). Data points for capsaicin response curves (C) were not normalized to second-pulse capsaicin (1 μM) since first-pulse capsaicin concentrations greater than 10 nM produced tachyphylaxis in the subsequent capsaicin (1 μM) response. For all experiments, n ≥ 3 trials/condition, about 100 cells/trial with each trial weighted to account for the number of cells.

Isoflurane Activates TRPV1 at High Concentrations.

Previous studies had found that VGAs such as isoflurane sensitized TRPV1 activity in the presence of other known TRPV1 agonists (Cornett et al., 2008); however, these studies were biased toward concentrations typically used in clinical settings. Since we found that chloroform activated TRPV1 at millimolar concentrations, we speculated that perhaps isoflurane might also activate TRPV1 at similar concentrations. Indeed, using ratiometric Ca2+ imaging, we found that isoflurane activated TRPV1 in a dose-dependent manner with an EC50 of 7.47 mM (Fig. 6, A and B). These data suggest that chloroform and isoflurane might use similar mechanisms to activate TRPV1.

Fig. 6.
Fig. 6.

Residues in the outer pore domain of TRPV1 necessary for activation by protons or heat are required for activation by chloroform and isoflurane. Responses of cells were assessed with ratiometric calcium imaging. (A) TRPV1-expressing HEK cells respond to isoflurane (12.2 mM) and capsaicin (1 μM). (B) Dose-response curve of TRPV1-expressing HEK cells to isoflurane. Peak isoflurane responses over baseline normalized to peak capsaicin (1 μM) responses (n ≥ 3 trials/concentration, about 100 cells/trial with each trial weighted to account for the number of cells). (C) TRPV1 mutants E600V, N628K, N652T, Y653T, and triple-heat mutant (N628K, N652T, Y653T) showed inhibited responses to chloroform (9.4 mM), whereas H378Q and E649Q did not differ from wild-type TRPV1. Peak chloroform over baseline responses normalized to peak capsaicin (1 μM) responses. Each bar represents an n ≥ 4 trials with about 100 cells/trial. (D) TRPV1 mutants E600V, N628K, N652T, Y653T, and triple-heat mutant (N628K, N652T, Y653T) showed inhibited responses to isoflurane (8.1 mM), whereas H378Q and E649Q did not differ from wild-type TRPV1. Peak isoflurane over baseline responses normalized to peak capsaicin (1 μM) responses. Each bar represents an n ≥ 4 trials, with about 100 cells/trial. **P < 0.01; ***P < 0.001. mt., mutant, wt, wild-type.

Mutations of Residues in the Outer Pore Domain Required for Heat or Acid Activation Impair Chloroform Activation of TRPV1.

To investigate what residues/domains of TRPV1 are required for chloroform-mediated activation of the channel, we characterized the response properties of previously described mutations that affect the ability of the channel to respond to specific stimuli using Ca2+ imaging. A concentration of 9.4 mM chloroform was used for these experiments since this concentration was near the top of the dose-response curve for TRPV1 activation. An intracellular amino-terminal mutation, H378Q, that specifically abrogates the ability of the channel to respond to basic pH, without affecting sensitivity to heat, acid, and capsaicin, had no effect on the ability of the channel to be activated by chloroform (wild-type [WT], 60.9 ± 4.6 a.u. versus H378Q, 66.7 ± 11.2 a.u.; P > 0.05. n ≥ 3 trials/concentration, about 100 cells/trial with each trial weighted to account for number of cells) (Fig. 6C) (Dhaka et al., 2009); however, when we tested a triple mutation of residues in the outer pore domain of TRPV1 (N628K, N652T, Y653T) that specifically impairs activation to heat by ablating temperature-dependent long channel openings without affecting responses to acid, or capsaicin, we observed a dramatically reduced sensitivity to chloroform (WT, 60.9 ± 4.6 a.u. versus N628K, N652T, Y653T, 17.4 ± 4.0 a.u.; P < 0.001. n ≥ 3 trials/concentration, ∼100 cells/trial with each trial weighted to account for the number of cells) (Fig. 6C) (Grandl et al., 2008). Furthermore, each individual mutation N628K, N652T, and Y653T demonstrated impaired responses to chloroform (WT, 60.9 ± 4.6 a.u. versus N628K, 7.0 ± 1.1 a.u., N625K, 22.1 ± 3.7 a.u. or Y653K 16.7, ± 4.6 a.u.; P < 0.0.001, P < 0.001, P < 0.001, respectively. n ≥ 3 trials/concentration, about 100 cells/trial with each trial weighted to account for number of cells) (Fig. 6C). This finding indicates that residues within the outer pore domain linked to heat activation of TRPV1 are required for normal sensitivity to chloroform. We next investigated the response to chloroform of a mutation to amino acid E600Q, which inhibits acid sensitivity while potentiating heat and capsaicin responsiveness (Jordt et al., 2000). It has been postulated that upon protonation of this residue, hydrogen bonds are disrupted which in turn facilitates gating associated movements of the outer pore and a widening of the selectivity filter (Cao et al., 2013a). As with the triple heat mutant, chloroform sensitivity was reduced by this mutation (WT 60.9 ± 4.6 a.u. versus E600Q 7.6 ± 1.1 a.u.; P < 0.001. n ≥ 3 trials/concentration, about 100 cells/trial with each trial weighted to account for number of cells) (Fig. 6C). We also tested the triple heat mutant TRPV1 (N628K, N652T, Y653T) for chloroform responsiveness at concentrations up to 12.5 mM (the maximum concentration we could use before we observed significant changes in intracellular calcium in HEK cells alone) and did not see any increase in activation compared with 9.4 mM chloroform (9.4 mM chloroform 17.5 ± 3.8 a.u. versus 12.5 mM chloroform 13.9 ± 4.5 a.u.; P > 0.05) (Supplemental Fig. 2). These data argue that the outer pore domain of TRPV1 is required for sensitivity to chloroform. A mutation of another residue (E649Q) that selectively abrogates proton sensitivity while maintaining normal heat and capsaicin responsiveness also located in the pore loop domain had no effect on chloroform mediated activation, suggesting that indiscriminate mutation of residues in the pore loop domain would not lead to selective reduction in TRPV1 sensitivity to chloroform (WT 60.9 ± 4.6 a.u. versus E649Q 51.0 ± 10.9 a.u.; P < 0.05) (Jordt et al., 2000).

We next assessed the effect these mutations had on TRPV1 sensitivity to isoflurane. Similar to chloroform, we chose a concentration of isoflurane (8.1 mM) that was near the top of the dose-response curve for isoflurane activation of TRPV1. In alignment with the findings from chloroform, the H378Q and E649Q mutations had no effect on the sensitivity to isoflurane, whereas the triple (N628K, N652T, Y653T), individual heat mutants (N628K, N652T, and Y653T) and E600V mutant were all deficient in their ability to respond to isoflurane (WT 41.7 ± 7.0 a.u. versus H378Q 41.8 ± 0.5 a.u, E649Q 41.9 ± 8.3 a.u., N628K N652T Y653T 2.5 ± 1.6 a.u., N628K 9.7 ± 3.8 a.u., N652T 9.5 ± 3.1 a.u., Y653T 9.5 ± 5.3 a.u., or E600V 7.8 ± 0.7 a.u.; P > 0.05, P > 0.05, P < 0.001, P < 0.01, P < 0.01, P < 0.001, or P < 0.01, respectively; n ≥ 3 trials/concentration, about 100 cells/trial, with each trial weighted to account for number of cells) (Fig. 6D), which would argue that isoflurane and chloroform interact with the outer pore domain of TRPV1 using overlapping determinants. Furthermore, our findings indicate that VGAs use structural determinants previously thought to be specific to protons or heat to activate the channel.

Discussion

TRPV1 and TRPA1 have a remarkable ability to detect a wide range of noxious stimuli (Julius, 2013). Here we have provided conclusive evidence that the environmental irritant and VGA chloroform activates TRPV1 while also functioning as a reversible antagonist of TRPA1 activity. We have shown that the responses of DRG neurons to chloroform are mediated mainly by TRPV1 as almost all neurons responding to chloroform also responded to the TRPV1 agonist capsaicin and pretreatment with the TRPV1 antagonist AMG9810 abrogated responses to chloroform. TRPM8, which is expressed a small percentage of DRG neurons (<10%), may also contribute to the response of DRG neurons to chloroform (Dhaka et al., 2008). Neurons expressing TRPM8 that were insensitive to capsaicin, thus not likely expressing TRPV1, also responded to chloroform.

It is well established that multiple agonists of TRPV1 can sensitize the activation of the channel by other agonists and that this cooperation is often synergistic as opposed to additive, arguing that the known different activator sites of these ligands are coupled within TRPV1 (Tominaga et al., 1998; Julius, 2013). We found that chloroform appears to sensitize the activation of TRPV1 by heat and protons, but under the testing conditions used in this study, chloroform appeared to have only additive effects upon activation by capsaicin. Why this may be warrants further investigation.

Although we have not determined the mechanisms by which chloroform activates TRPV1, it is more likely than not that chloroform activates TRPV1 via a ligand gating mechanism, which would align with previous findings on VGA activation of TRP channels and the action of other membrane-partitioning compounds, such as camphor on TRPV1 activation (Matta et al., 2008; Marsakova et al., 2012). This also corresponds with many studies that suggest that chloroform and other VGAs act on transmembrane receptors and ion channels such as the GABA receptors, NMDA receptors, and two-pore domain potassium channels via ligand receptor binding dynamic (Franks and Lieb, 1994; Franks, 2008). Others, however, point to the lipophilic properties of chloroform and have shown that chloroform readily inserts itself into the plasma membrane, causing a loosening and rearrangement of the plasma membrane (Turkyilmaz et al., 2009; Reigada, 2011).These studies argue that this could lead to relaxed and dysfunctional transmembrane proteins, which in turn would account for the anesthetic effects of chloroform and other VGAs. Like chloroform, high temperatures are known to fluidize and increase disorder in the plasma membrane, whereas cooling temperatures lead to increased rigidity and stiffen the plasma membrane (Digel et al., 2008). It has been proposed that thermoTRP channel activity in response to changes in temperature may be mediated by temperature-dependent alterations in their interactions with the plasma membrane (Clapham, 2003). Recently, however, it was shown that artificial liposomes containing purified TRPV1 display intrinsic heat sensitivity that is not altered by changes in lipid bilayer tension (Cao et al., 2013b). Nevertheless, since heat-activated TRPV1 was activated by chloroform and cold-activated TRPA1 was inhibited, we considered that alterations in membrane fluidity by chloroform could mimic the effects of temperature on these channels such that increasing membrane fluidity would lead to TRPV1 activation and perhaps inhibition of TRPA1 activation. At the time, we reasoned that if this was true, other structurally similar heat-activated TRPV channels, such as the warm-activated channels TRPV3 and TRPV4, as well as the high heat-threshold channel TRPV2 might be activated by lower to higher concentrations of chloroform, respectively, and perhaps cool-activated TRPM8 might be inhibited by chloroform (Dhaka et al., 2006). This was not the case; TRPV2, TRPV3, and TRPV4 were not activated by chloroform. Additionally, cool-activated TRPM8 was activated by chloroform, which would not be expected if decreasing membrane fluidity by cooling temperatures were responsible for activation of this channel. These data argue that chloroform does not activate TRPV1 or inhibit TRPA1 by mimicking the effects of temperature on plasma membrane fluidity, nor does it provide any evidence that temperature might activate thermoTRPs by modulating membrane fluidity.

We have shown that residues in the outer pore region previously thought to be required for specific activation by either heat or protons are critical for activation by the VGAs chloroform and isoflurane (Jordt et al., 2000; Grandl et al., 2010). Intriguingly, structural analysis of TRPV1 suggests that residue E600 required for proton and VGA activation and residue Y653 required for heat and VGA activation of TRPV1 could potentially form a hydrogen bond that upon disruption could lead to the facilitation of channel activation. Indeed it has been postulated that protonation of E600 disrupts this bond leading to channel activation (Cao et al., 2013a). One possibility is that chloroform and isoflurane interaction with TRPV1 could lead to the disruption of this hydrogen bond, potentiating channel activation. In the future, it will be interesting to determine whether specific residues in the outer pore region are required for chloroform activation of TRPM8.

In summary, our results show that chloroform excites somatosensory neurons by activating TRPV1; however, chloroform has divergent effects on TRP family members in vitro. It has no effect on warm-sensitive TRPV3 or TRPV4 channels or high heat-activated TRPV2. In addition to TRPV1, chloroform activates TRPM8, and unlike other VGAs such as isoflurane, which activate TRPA1, chloroform is a potent inhibitor of TRPA1. Finally, we show that chloroform and isoflurane use overlapping determinants in the outer pore loop region to activate TRPV1.

Authorship Contributions

Participated in research design: Dhaka, Hu, Kimball.

Conducted experiments: Kimball, Luo, Yin.

Performed data analysis: Kimball, Luo, Yin.

Wrote or contributed to the writing of the manuscript: Dhaka, Kimball.

Footnotes

Abbreviations

AITC
allyl isothiocyanat
a.u.
absorbance unit
AMG9810
(2E)-N-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[4-(1,1-dimethylethyl)phenyl]-2-propenamide
DMEM
Dulbecco’s modified Eagle’s medium
DRG
dorsal root ganglion
EGFPf
green fluorescent protein farnesylated
GSK1016790A
GSK101, N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide
HC-030031
2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl)acetamide
HEK
human embryonic kidney
TRP
transient receptor potential
VGA
volatile general anesthetic

References

  1. ↵
    1. Bautista DM,
    2. Jordt SE,
    3. Nikai T,
    4. Tsuruda PR,
    5. Read AJ,
    6. Poblete J,
    7. Yamoah EN,
    8. Basbaum AI, and
    9. Julius D
    (2006) TRPA1 mediates the inflammatory actions of environmental irritants and proalgesic agents. Cell 124:1269–1282.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Campbell JN,
    2. Raja SN, and
    3. Meyer RA
    (1984) Halothane sensitizes cutaneous nociceptors in monkeys. J Neurophysiol 52:762–770.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Cao E,
    2. Cordero-Morales JF,
    3. Liu B,
    4. Qin F, and
    5. Julius D
    (2013b) TRPV1 channels are intrinsically heat sensitive and negatively regulated by phosphoinositide lipids. Neuron 77:667–679.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Cao E,
    2. Liao M,
    3. Cheng Y, and
    4. Julius D
    (2013a) TRPV1 structures in distinct conformations reveal activation mechanisms. Nature 504:113–118.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Caterina MJ,
    2. Leffler A,
    3. Malmberg AB,
    4. Martin WJ,
    5. Trafton J,
    6. Petersen-Zeitz KR,
    7. Koltzenburg M,
    8. Basbaum AI, and
    9. Julius D
    (2000) Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 288:306–313.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Clapham DE
    (2003) TRP channels as cellular sensors. Nature 426:517–524.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Cornett PM,
    2. Matta JA, and
    3. Ahern GP
    (2008) General anesthetics sensitize the capsaicin receptor transient receptor potential V1. Mol Pharmacol 74:1261–1268.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Dhaka A,
    2. Earley TJ,
    3. Watson J, and
    4. Patapoutian A
    (2008) Visualizing cold spots: TRPM8-expressing sensory neurons and their projections. J Neurosci 28:566–575.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Dhaka A,
    2. Uzzell V,
    3. Dubin AE,
    4. Mathur J,
    5. Petrus M,
    6. Bandell M, and
    7. Patapoutian A
    (2009) TRPV1 is activated by both acidic and basic pH. J Neurosci 29:153–158.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Dhaka A,
    2. Viswanath V, and
    3. Patapoutian A
    (2006) Trp ion channels and temperature sensation. Annu Rev Neurosci 29:135–161.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Digel I,
    2. Kayser P, and
    3. Artmann GM
    (2008) Molecular processes in biological thermosensation. J Biophys 2008:602870.
    OpenUrlPubMed
  12. ↵
    1. Eger EI 2nd.
    (1995) New drugs in anesthesia. Int Anesthesiol Clin 33:61–80.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Eilers H,
    2. Cattaruzza F,
    3. Nassini R,
    4. Materazzi S,
    5. Andre E,
    6. Chu C,
    7. Cottrell GSPD,
    8. Schumacher M,
    9. Geppetti P, and
    10. Bunnett NWPD
    (2010) Pungent general anesthetics activate transient receptor potential-A1 to produce hyperalgesia and neurogenic bronchoconstriction. Anesthesiology 112:1452–1463.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Franks NP
    (2008) General anaesthesia: from molecular targets to neuronal pathways of sleep and arousal. Nat Rev Neurosci 9:370–386.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Franks NP and
    2. Lieb WR
    (1994) Molecular and cellular mechanisms of general anaesthesia. Nature 367:607–614.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Gavva NR,
    2. Tamir R,
    3. Qu Y,
    4. Klionsky L,
    5. Zhang TJ,
    6. Immke D,
    7. Wang J,
    8. Zhu D,
    9. Vanderah TW,
    10. Porreca F,
    11. et al.
    (2005) AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties. J Pharmacol Exp Ther 313:474–484.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Grandl J,
    2. Hu H,
    3. Bandell M,
    4. Bursulaya B,
    5. Schmidt M,
    6. Petrus M, and
    7. Patapoutian A
    (2008) Pore region of TRPV3 ion channel is specifically required for heat activation. Nat Neurosci 11:1007–1013.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Grandl J,
    2. Kim SE,
    3. Uzzell V,
    4. Bursulaya B,
    5. Petrus M,
    6. Bandell M, and
    7. Patapoutian A
    (2010) Temperature-induced opening of TRPV1 ion channel is stabilized by the pore domain. Nat Neurosci 13:708–714.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Hu HZ,
    2. Gu Q,
    3. Wang C,
    4. Colton CK,
    5. Tang J,
    6. Kinoshita-Kawada M,
    7. Lee LY,
    8. Wood JD, and
    9. Zhu MX
    (2004) 2-Aminoethoxydiphenyl borate is a common activator of TRPV1, TRPV2, and TRPV3. J Biol Chem 279:35741–35748.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Jordt SE,
    2. Tominaga M, and
    3. Julius D
    (2000) Acid potentiation of the capsaicin receptor determined by a key extracellular site. Proc Natl Acad Sci USA 97:8134–8139.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Julius D
    (2013) TRP channels and pain. Annu Rev Cell Dev Biol 29:355–384.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Li LH,
    2. Jiang XZ,
    3. Liang YX,
    4. Chen ZQ,
    5. Zhou YF, and
    6. Wang YL
    (1993) Studies on the toxicity and maximum allowable concentration of chloroform. Biomed Environ Sci 6:179–186.
    OpenUrlPubMed
  23. ↵
    1. Lynch C 3rd.
    (2008) Meyer and Overton revisited. Anesth Analg 107:864–867.
    OpenUrlCrossRefPubMed
  24. ↵
    1. MacIver MB and
    2. Tanelian DL
    (1990) Volatile anesthetics excite mammalian nociceptor afferents recorded in vitro. Anesthesiology 72:1022–1030.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Marsakova L,
    2. Touska F,
    3. Krusek J, and
    4. Vlachova V
    (2012) Pore helix domain is critical to camphor sensitivity of transient receptor potential vanilloid 1 channel. Miscellaneous Article Anesthesiology 116:903–917.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Matta JA,
    2. Cornett PM,
    3. Miyares RL,
    4. Abe K,
    5. Sahibzada N, and
    6. Ahern GP
    (2008) General anesthetics activate a nociceptive ion channel to enhance pain and inflammation. Proc Natl Acad Sci USA 105:8784–8789.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. McKemy DD,
    2. Neuhausser WM, and
    3. Julius D
    (2002) Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature 416:52–58.
    OpenUrlCrossRefPubMed
  28. ↵
    1. McNamara CR,
    2. Mandel-Brehm J,
    3. Bautista DM,
    4. Siemens J,
    5. Deranian KL,
    6. Zhao M,
    7. Hayward NJ,
    8. Chong JA,
    9. Julius D,
    10. Moran MM,
    11. et al.
    (2007) TRPA1 mediates formalin-induced pain. Proc Natl Acad Sci USA 104:13525–13530.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Mutoh T,
    2. Tsubone H,
    3. Nishimura R, and
    4. Sasaki N
    (1998) Responses of laryngeal capsaicin-sensitive receptors to volatile anesthetics in anesthetized dogs. Respir Physiol 111:113–125.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Peier AM,
    2. Moqrich A,
    3. Hergarden AC,
    4. Reeve AJ,
    5. Andersson DA,
    6. Story GM,
    7. Earley TJ,
    8. Dragoni I,
    9. McIntyre P,
    10. Bevan S,
    11. et al.
    (2002) A TRP channel that senses cold stimuli and menthol. Cell 108:705–715.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Reigada R
    (2011) Influence of chloroform in liquid-ordered and liquid-disordered phases in lipid membranes. J Phys Chem B 115:2527–2535.
    OpenUrlPubMed
  32. ↵
    1. Story GM,
    2. Peier AM,
    3. Reeve AJ,
    4. Eid SR,
    5. Mosbacher J,
    6. Hricik TR,
    7. Earley TJ,
    8. Hergarden AC,
    9. Andersson DA,
    10. Hwang SW,
    11. et al.
    (2003) ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell 112:819–829.
    OpenUrlCrossRefPubMed
  33. ↵
    1. TerRiet MF,
    2. DeSouza GJ,
    3. Jacobs JS,
    4. Young D,
    5. Lewis MC,
    6. Herrington C, and
    7. Gold MI
    (2000) Which is most pungent: isoflurane, sevoflurane or desflurane? Br J Anaesth 85:305–307.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Thorneloe KS,
    2. Sulpizio AC,
    3. Lin Z,
    4. Figueroa DJ,
    5. Clouse AK,
    6. McCafferty GP,
    7. Chendrimada TP,
    8. Lashinger ESR,
    9. Gordon E,
    10. Evans L,
    11. et al.
    (2008) N-((1S)-1-[4-((2S)-2-[(2,4-dichlorophenyl)sulfonyl]amino-3-hydroxypropanoyl)-1-piperazinyl]carbonyl-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a novel and potent transient receptor potential vanilloid 4 channel agonist induces urinary bladder contraction and hyperactivity: Part I. J Pharmacol Exp Ther 326:432–442.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Tominaga M,
    2. Caterina MJ,
    3. Malmberg AB,
    4. Rosen TA,
    5. Gilbert H,
    6. Skinner K,
    7. Raumann BE,
    8. Basbaum AI, and
    9. Julius D
    (1998) The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 21:531–543.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Vanden Abeele F,
    2. Kondratskyi A,
    3. Dubois C,
    4. Shapovalov G,
    5. Gkika D,
    6. Busserolles J,
    7. Shuba Y,
    8. Skryma R, and
    9. Prevarskaya N
    (2013) Complex modulation of the cold receptor TRPM8 by volatile anaesthetics and its role in complications of general anaesthesia. J Cell Sci 126:4479–4489.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Turkyilmaz S,
    2. Chen W-H,
    3. Mitomo H, and
    4. Regen SL
    (2009) Loosening and reorganization of fluid phospholipid bilayers by chloroform. J Am Chem Soc 131:5068–5069.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Winslow SG and
    2. Gerstner HB
    (1978) Health aspects of chloroform: a review. Drug Chem Toxicol 1:259–275.
    OpenUrlCrossRefPubMed
View Abstract
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools
Research ArticleArticle

VGAs Activate TRPV1 via Pore Loop Domain

Corinna Kimball, Jialie Luo, Shijin Yin, Hongzhen Hu and Ajay Dhaka
Molecular Pharmacology July 1, 2015, 88 (1) 131-138; DOI: https://doi.org/10.1124/mol.115.098277
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section